Table 1.
Cohort characteristics for the hospitalization risk studies.
| Cohort 1 (n = 9,493) | Cohort 2 (n = 1,581) | |||||
|---|---|---|---|---|---|---|
| Hospitalized patients | Non-hospitalized patients | Two-sided p-value | Hospitalized patients | Non-hospitalized patients | Two-sided p-value | |
| COVID-19 positive | 3,183 | 6,310 | N/A | 581 | 1,000 | N/A |
| Males (%) | 1,549 (48.7%) | 2,758 (43.7%) | 5.0e-06 | 295 (50.1%) | 348 (34.8%) | 6.5e-10 |
| Median Age (Range) | 75 (29–89) | 72 (15-89) | <2.2e-16 | 74 (31–89) | 71.5 (33–89) | 2.2e-14 |
| Caucasian* (%) | 1,632 (66.7%) | 3,693 (66.8%) | 0.938 | 298 (57.5%) | 528 (59.5%) | 0.465 |
| Mortality (%) | 607 (19.10%) | N/A | N/A | 100 (17.2%) | N/A | N/A |
| Hypertension (%) | 1,657 (52.1%) | 3,864 (61.2%) | <2.2e-16 | 431 (58.7%) | 672 (67.2%) | 3.7e-03 |
| Diabetes (%) | 1,109 (34.8%) | 2,114 (33.5%) | 0.198 | 277 (47.7%) | 427 (42.7%) | 5.8e-02 |
| Cardiovascular (%) | 1,210 (38.0%) | 1,468 (23.3%) | <2.2e-16 | 204 (35.1%) | 267 (26.7%) | 2.2e-03 |
| Dementia (%) | 443 (13.9%) | 236 (3.7%) | <2.2e-16 | 27 (4.6%) | 10 (1.0%) | 7.2e-06 |
| Chronic lung disease (%) | 832 (25.9%) | 1,198 (20.0%) | 2.4e-15 | 135 (23.2%) | 188 (18.9%) | 3.8e-02 |
*
The percentage of Caucasians was calculated as a fraction of those individuals for whom ethnicity information was available (~85% of all records).
p-values were calculated to assess the association of each feature in the two COVID-19 hospitalized risk cohorts using two-sided Fisher's exact tests for categorical data and Mann-Whitney U tests for continuous data.